Chairman of the Positron Corporation (OTCBB: POSC) Confirms Talks; Sources Say Partnership or Buy-Out News May Follow Next Week
LOS ANGELES, CA -- (Marketwire) 04/22/10 As rumors of a lucrative buy-out or partnership continue to swirl, Patrick G. Rooney, the Chairman of the Board of Positron Corporation (OTCBB: POSC) -- a molecular imaging company focused on Nuclear Cardiology -- has confirmed in an interview with BioMedReports that his company "is currently in discussions with a potential partner in our industry."
While Rooney did not offer any assurances or details about when an agreement might be reached. Over the past two weeks, however, multiple sources have told the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors that details about "a big announcement involving Positron and a much larger publicly traded NYSE company" could come as early as next Monday.
BioMedReports told its subscribers on Wednesday that stock prices for the twenty-seven-year-old company could see substantial gains now that the company had positioned itself to be the leader in nuclear cardiology imaging. Positron's PET scanner, known as the "Attrius," has robust cardiac specific imaging software and, more importantly, is the only "PET" imaging device in the industry.
In a letter to shareholders last month, Rooney informed investors that "Positron has several immediate opportunities with some of the largest companies in the nuclear medicine industry. Any combination of success with these opportunities will have a tremendous positive present and future impact on Positron."
According to today's exclusive report, Rooney feels confident that his company will thrive financially given that "the cardiac business is five times greater than the oncology business."
"Everyone has a heart problem; not everyone has cancer," said Rooney. "Once you have a heart issue, they'll put you on some kind of imaging device to test your heart. It's just where medicine is going. Everyone over 45 or so is starting to get imaged at the first sign of any heart issues."
Positron recently won the 2010 Frost and Sullivan "North American Molecular Imaging Systems New Product Innovation Award."
The complete special report and video about the company is available at BioMedReports.Com.
Biotech investors interested in accessing the news portal's database of clinical trials and upcoming FDA decisions can access that information here: